TQB3019 / Sino Biopharm - LARVOL DELTA

Preclinical development of TQB3019: A potent and selective oral BTK degrader leveraging the OAPD® platform to overcome acquired resistance mutations (AACR 2025) - "Unlike covalent inhibitor ibrutinib, TQB3019 also demonstrated improved selectivity for BTK over TEC. TQB3019 using a novel designed CRBN ligand showed over 14-fold higher binding affinity to CRBN protein compared to pomalidomide... Developed using Chia Tai Tianqing's OAPD® platform, TQB3019 is an orally available BTK degrader with promising potency, superior selectivity, and favorable pharmacological properties. With IND (Investigational New Drug) application forthcoming, TQB3019 represents a promising therapeutic candidate to address resistance challenges associated with traditional BTK inhibitors."

Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lung Cancer • Oncology • Solid Tumor • CRBN • EGFR • IKZF1

A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Oncology • Solid Tumor

APPLICATION FOR CLINICAL TRIAL OF “TQB3019 (BTK PROTAC)” APPROVED BY NMPA (HKEXnews) - "The board of directors (the 'Board') of Sino Biopharmaceutical Limited (the 'Company', together with its subsidiaries, the 'Group') announces that the Group’s self-developed 'TQB3019 (BTK PROTAC)' has been approved for clinical trial by the National Medical Products Administration (NMPA) of China. The drug is intended for use in the treatment of hematologic tumours."

New trial • Hematological Malignancies